Sistemic announces companion biomarker programme

Published: 4-Jul-2011
Research & Development

Extends miRNA drug discovery toolkit

Sistemic, a global company with expertise in microRNA, has released a new companion biomarker programme, which extends its SistemRNA suite of drug discovery and development tools.

The firm, based in Glasgow in Scotland and Boston, US, says this programme simplifies the benefits of miRNA analysis and profiling to support timely decision making within clinical research. The new multiple miRNA biomarkers can be used to determine the efficacy of targeted drugs, in major therapeutic areas and when developing companion biomarker strategies for future clinical development.

Companion biomarkers are the most recent extension of microRNA technology and are set to provide valuable clinical data to guide both pre-clinical and clinical studies.

The firm says the system will use miRNA to identify highly discriminatory biomarkers, which, in turn, will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response.

  • Companies:
  • Sistemic
See more

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Read more
Cell therapy companies to be offered a streamlined process for clinical trials

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
  4. Five critical design elements for Pelton wheel turbine flowmeters Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
  5. Anton Paar expands Litesizer DIA Series with new models Introducing affordable and advanced solutions for particle analysis

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Cell therapy companies to be offered a streamlined process for clinical trials
Research & Development

Sistemic cuts cost of drug discovery

Launches microRNA technology to filter out harmful compounds early in development process
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now